text:
Read more: Click here to read the original, longer version of this story
AS THE dust settles on the US presidential election (see "Cannabis legalisation launches living laboratory" and "Winning the next election could be all about statistics"), a train wreck looms for science and the wider economy.
Savage cuts in federal budgets, known as the "fiscal cliff", will kick in automatically if Congress can't reach a deal by the end of the year to reduce the deficit. With social security and government health programmes shielded, science budgets would be among those bearing the brunt. "It's imperative to avoid the fiscal cliff, which would be devastating," says Mary Woolley of Research!America.
If the cliff is avoided, there are small signs that science may get a better hearing from US politicians in future. Several people known for their unscientific views did poorly at the polls, including four Republicans who deny the existence of climate change, who were ousted from the House of Representatives.
- Subscribe to New Scientist and you'll get:
- New Scientist magazine delivered every week
- Unlimited access to all New Scientist online content -
a benefit only available to subscribers
- Great savings from the normal price
- Subscribe now!
If you would like to reuse any content from New Scientist, either in print or online, please contact the syndication department first for permission. New Scientist does not own rights to photos, but there are a variety of licensing options available for use of articles and graphics we own the copyright to.


text: Perianesthesia Certification Review: CPAN/CAPA Overview Fees Travel Info Speakers Accreditation Register Schedule August 1, 2015 February 20, 2016 July 30, 2016 February 18, 2017 Drexel University Center City Campus Philadelphia, PA Available via Webcast. Select webcast option during online registration or indicate on registration form. PROGRAM DESCRIPTION: Perinanethesia Certification Review includes a review of topics important for the Certified Post anesthesia Nurse (CPAN) certification exam and the Certified Ambulatory Perianesthesia Nurse (CAPA) certification exam offered by the American Board of Perianesthesia Nursing. TARGET AUDIENCE: All perianesthesia nurses. PROGRAM TOPICS: Anesthetic Agents and Techniques Complications Hemodynamic Monitoring Preop Preparation, Patient Education, Discharge Legal, Ethics, Research, Management Acid Base Balance and ABG Interpretation ASPAN Standards Test Taking Techniques PROGRAM SCHEDULE: 8:00 a.m. – 5:45 p.m. Testimonials Testimonials "Despite 5 years of PACU nursing, I did not have a complete understanding of anesthetic medications until this review course. The speakers are phenomenal, the information clearly presented, and the materials useful. I would recommend this class to any nurse preparing for the CPAN/CAPA exam." - J. Thomas, Philadelphia, PA "Well done, in-depth course to prepare for certification . . . Knowledge is enhanced and anxiety is reduced!" - P. Lefever, Morristown, NJ Fees $159.00 Tuition Includes Comprehensive Program Book with all handouts Continental Breakfast & Refreshment Breaks Contact Hour Certificate Travel Info Directions Directions to Drexel's Center City Campus Discounted Hotel Rates Drexel University has discounted rates with hotels in Philadelphia. Please visit the Drexel University Procurement web page. Speakers Linda Wilson, RN, PhD, CPAN, CAPA, BC, CNE, CHSE, CHSE-A, ANEF, FAAN H. Lynn Kane, MSN, MBA, RN, CCRN Accreditation Purpose: To enable the nurse to demonstrate competence through success on the perianesthesia certification exam. Overall program objective: Discuss topics important for the CPAN and CAPA perianesthesia certification exams. Contact hours: 8.0 Continuing Nursing Education contact hours will be provided. You must attend the entire program to receive credit. Accreditation: Drexel University (DREXEL) College of Nursing and Health Professions, Division of Continuing Nursing Education is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation. DREXEL also has provider status with California BRN: Provider #CEP13661. Disclosure statement: All planners and presenters at nursing continuing education activities are required to disclose to the audience any significant financial relationships with the manufacturer(s) of any commercial products, goods or services. Such disclosures will be made in writing in the course presentation materials. Commercial support: No commercial support was received for this program. Sponsorship: No sponsorship was received for this program. Unrestricted Educational Grant: No unrestricted educational grant was received for this program. Register Dates Location Register August 1, 2015 Philadelphia, PA Online Mail-In February 20, 2016 Drexel University Center City Campus Online Mail-In August 1, 2015 CPAN-CAPA Cert Review Course ScheduleFebruary 20, 2016 CPAN-CAPA Cert Review Course

subset: commoncrawl


text: If I'd known this all along I think I would have spent a lot more time at Grandma's house. I thought she just baked cookies and knit all day. I mean…don't get me wrong, her oatmeal cookies are awesome but nothing could be this. Apparently the really is more than meets the eye.


text:
I'm Greg McBride, senior financial analyst with Bankrate.com and here is your weekly look at mortgage rates.
For the most part, mortgage rates inched lower this week. The average 30-year fixed mortgage rate is now 5.07 percent. On larger loans, the average jumbo 30-year fixed rate is now 5.55 percent. And the gap between fixed and adjustable rate loans continues to grow, with the average 5-year adjustable rate dipping to 3.83 percent.
The lone wolf this week was the 15-year fixed mortgage that is popular for refinancing, where the average rate was a tick higher to 4.28 percent.
The movement in mortgage rates has been tame in recent weeks. Rates have been range-bound, having remained within a one-quarter percentage point band over the past 2 months. Historically, we've seen rates do very little for an extended period of time but then move significantly in a relatively short period of time. If upcoming inflation numbers spook the markets, for example, that could be the catalyst for a sudden move.
A tiny difference in rate can mean big savings over time, so it's important to shop around for the best deal. To check mortgage rates in your area, be sure to go to Bankrate.com.
I'm Greg McBride.
Bankrate wants to hear from you and encourages thoughtful and constructive comments. We ask that you stay focused on the story topic, respect other people's opinions, and avoid profanity, offensive statements, illegal contents and advertisement posts. Comments are not reviewed before they are posted. Bankrate reserves the right (but is not obligated) to edit or delete your comments. Please avoid posting private or confidential information, and also keep in mind that anything you post may be disclosed, published, transmitted or reused. We do not permit the inclusion of hyperlinks in comments and may remove any comment that includes a hyperlink.
By submitting a post, you agree to be bound by Bankrate's terms of use. Please refer to Bankrate's privacy policy for more information regarding Bankrate's privacy practices.
Timely market news and advice for consumers ready to buy, sell or invest in real estate. Delivered weekly.
If you are looking for a mortgage, make sure to avoid these common mistakes.
... Read more


text:
Prosecutors to seek death for Boston bombing suspect
Attorney General Eric Holder decided that federal prosecutors will seek execution for Dzhokhar Tsarnaev.
Stories about the tragic Boston Marathon bombing
Attorney General Eric Holder decided that federal prosecutors will seek execution for Dzhokhar Tsarnaev.
A Chechen immigrant was shot to death by authorities while being questioned in the Boston Marathon bombing case early Wednesday after he all…
With the Boston Marathon bombing still fresh in people's minds, organizers for Sunday's Rock 'n' Roll Half Marathon worked with the Portland…
Prosecutors agreed that one of the friends of Boston Marathon suspect Dzhokhar Tsarnaev should be released from federal custody under strict…
Federal authorities on Wednesday arrested three college friends of Dzhokhar Tsarnaev.
Their identities were not disclosed. Three people were killed and more than 260 injured in the April 15 explosions.
They are donating 30 percent of their sales Tuesday to The One Fund.
Dzhokhar Tsarnaev reportedly told Boston investigators from his hospital bed that he and his brother had discussed going to New York to deto…
More than 8,500 runners are expected. The Oregon National Guard will supplement a large contingent of police officers.
It pulled T-shirts emblazoned with the words 'Boston Massacre,' featuring blood-splattered lettering designed for New York Yankees fans.


text:
My lo is 8 months old & is wearing size 4 diapers about 2 buy size 5 after this box runs out. He's wearing 12 & 18 month clothes depending on the brand & type, needed more than for width rather than length.
What size clothes & diapers are ur LOs wearing?
Posted 03/25/2013
We are size 2 during the day and 3 at night. He wears 3, 3-6 and 6 months clothes depending on the brand and type of clothes.
It's almost time!
cjainusa · Original Poster
Posted 03/25/2013
Wow seems like a wide variety amongst our babies.
Mystolensecret - my lo has his dad's big butt & thighs. My dh isn't fat just muscular in his butt & thighs cuz he runs a lot & does squats! My lo has a butt crack that's a mile long. Lol
Mystolensecret - my lo has his dad's big butt & thighs. My dh isn't fat just muscular in his butt & thighs cuz he runs a lot & does squats! My lo has a butt crack that's a mile long. Lol
Posted 03/25/2013
Titus is 8.5 months old and is in size 3 diapers and wears mostly 6-9 month clothes, but can fit some 12 month. Sometimes it just depends on the brand! At his check up today they said he's 21 pounds.
Gideon (9-30-14)
Katie (21) and Billy (23) est. May 2008, married November 2010
Titus (7-12-12)
Gideon (9-30-14)
Posted 03/25/2013
Oh yeah, 6-9 month clothes, but the pants are like capris on her. 12 month clothes are too huge.
Posted 03/25/2013
Size 5 diapers! And 18-24 month clothes! (Depends on the brand.) he's a very tall boy!
Posted 03/25/2013
My son is 8 months and wears 6-9 months and size 3 diapers.
Married to my highschool sweetheart since 1993 DS 1993 - DD 1998 - DD 2001 - DD 2009 - DS 2012 - DS due 2-24-15 Mommy of Five beautiful babies!!!!
Last edited 03/25/2013
Most clothes is 6-9 months. She has a few 3-6 that fits, but those are on the big side. Zize 3 diapers, but we're probably going up to 4. My LO has some thick thighs.
Mommy to October 15th DS 2014!! (.Y.) Silver
Mommy to Independence Day DD 2012 (.Y.) Platinum
Posted 03/25/2013
He is in size 3 diapers and wears both 6-9 month clothes and 12 month clothes.
Posted 03/25/2013
Almost in size 5 diapers and 9 & 12 month clothes but I'll have to get rid of the 9 month because she's growing tall so the pants are getting too short
What's on your mind?Create a new post
Your growing child
Your 33-month-old: Language milestones
Signs that your child's language skills are on track Read More
Your 34-month-old: Beating bossiness
Strategies for dealing with bossiness Read More
Your 34-month-old: Preschooler humor
Take advantage of your child's growing sense of humor Read More
Your 34-month-old: Tracking growth
How can you tell if your child is the proper weight? Read More
Your 34-month-old: Potty mouth
You're so proud of your angel's growing vocabulary — until words like "poopie head" and worse creep in. Read More


text:
Narrow your search
Although it's pricey, the Sony DVDirect VRD-MC3 is a boon for anyone who has lots of old videotapes but less time or tech skills to digitize them using a computer. Even better, it doubles as an external DVD burner, so you can use it with your PC long after you've transferred all those old tapes.
The Sony DVDirect does an admirable job of transferring footage directly from a camcorder to a DVD without using a PC, but editing capabilities are sacrificed for the sake of simplicity.
The Sony VRD-MC6 is a standalone DVD burner that can capture video (and photos!) from just about any source, including camcorders, VCRs, and memory cards.
Sony's new VRD-MC5 DVDirect offers HD support and additional features.
New non-PC DVD recorder is on the way from Sony.


text:
Jim Rausch accepted a call in November 2011 to become pastor of First Presbyterian Church in Muskegon, MI. He lives with his wife Chris and two children, Jennica and Jacob, in Muskegon and may be reached at firstname.lastname@example.com.
Dan Palmer led the Case Western Reserve University men's soccer team to a second University Athletic Association (UAA) title. In his eighth season as head men's soccer coach, he coached the UAA most valuable player for the second consecutive year and coached the co-rookie of the year for the first time in program history. Palmer has also coached four All-Americans. He and his staff were also honored as the UAA Co-Coaching Staff of the Year. He lives in Medina, Ohio, and may be reached at firstname.lastname@example.com.
A North Central College conference showcased the scholarly work of professors, whose academic pursuits include conducting research, writing fiction and nonfiction and creating works of art.
"A Promising Start: Excellence in Scholarship" on Sept. 4 featured panel discussions, poster presentations and sessions during which nearly 40 faculty members shared stories and findings of their independent scholarly work.
Several student broadcasters representing WONC-FM 89.1, North Central College's student-run radio station, have earned nominations in state and national competitions.
In a state competition, eight students earned six nominations in five different categories in the annual Student Silver Dome Awards presented each fall by the Illinois Broadcasters Association to the top college and university radio and TV programs in the state. The awards will be presented in a luncheon ceremony Sept. 21 at Illinois State University in Normal.
North Central College is being nationally recognized as a College of Distinction for 2012-2013.
Colleges of Distinction is a college guide that considers the views of guidance counselors, educators and admissions professionals to honor colleges that excel in four areas of undergraduate education: student engagement in the educational process, great teaching, vibrant learning communities and successful outcomes.
Community members are invited to hear faculty members discuss recent books they've authored, present findings of their scholarly research and talk about partnerships with local organizations during an academic conference Sept. 4 at North Central College.
The Princeton Review has once again named North Central College a Best Midwestern College in its annual survey of the nation's best colleges.
North Central College is among a select group of institutions nationwide highlighted by The Princeton Review in "The Best 377 Colleges, 2013 Edition."
Only about 15 percent of America's 2,500 four-year colleges are profiled in the book, which is based on the Princeton Review's surveys of 122,000 college students. The Princeton Review began surveying college students and publishing its findings in 1992.
Aaron S. Williams, director of the Peace Corps, will deliver the address June 9 at the 147th Commencement ceremony of North Central College.
David DePino of Wheaton was awarded the 2012 Outstanding Student in Forensics Award during Honors Day May 15 at North Central College.
DePino is a senior with majors in history and political science at North Central College. He is the son of Mark and Davida DePino and is a 2009 graduate of Wheaton North High School.
May 22, 2012—Derrick Wynn of Darien was awarded the 2012 Outstanding Major in Communication Award during Honors Day May 15 at North Central College.
Wynn is a senior majoring in speech communication with a minor in philosophy at North Central College. He has been accepted to Worsham College in Wheeling where he will study mortuary science. He is the son of Robert and Susan Wynn and is a 2008 graduate of Downers Grove South High School.
North Central College prepares students to be informed,
involved, principled and productive citizens and leaders over their lifetime.


text:
advertise on this site | login
3 businesses for sale in this list : Page 1 of 1
Showing all types of businesses for sale in Bristol (Area)
Alter Order by: Last Updated Insertion Date Reference ID
Business For Sale : EXCEPTIONAL CAFE/SANDWICH BARLocation : Bristol, Bristol (City), UK
Freehold | Asking Price: £525,000
High amount of regular & repeat trade
2 bedroom owners' accommodation
Advised annual turnover of £319,739
Scope for further development
Ideal partnership opportunity
Situated in the city of Bristol
Genuine reason for sale
FREEHOLDMore Details...Contact: Meridian Business Sales LtdFax: 0845 222 0509 Send a Message to this Advertiser
[Advert Ref: BFS:3665]
Business For Sale : WELL ESTABLISHED GREENGROCERSLocation : Bristol (Area), UK
Leasehold | Asking Price: £49,995
Situated in the desirable suburb of Stoke Bishop
Well established and highly regarded business
Well presented and appointed throughout
Early viewing essential to fully appreciate
Genuine reason for sale due to retirement
High amount of regular & repeat trade
Advised annual turnover of £135,000
Ideal partnership opportunity
LEASEHOLDMore Details...Contact: Meridian Business Sales LtdFax: 0845 222 0509 Send a Message to this Advertiser
[Advert Ref: BFS:3905]
Business For Sale : CAFE WITH LARGE PRIVATE LIVING SPACELocation : Bristol (Area), UK
Freehold | Asking Price: £375,000
Advised weekly turnover of £1,300 with good GP returns
Early interest and viewing is highly recommended
Very well presented and appointed throughout
Ideal high footfall location in Fishponds, Bristol
Sale price includes all fixtures and fittings
Ideal lifestyle change opportunity
Superb first business opportunity
Genuine reason for sale
FREEHOLDMore Details...Contact: Meridian Business Sales LtdFax: 0845 222 0509 Send a Message to this Advertiser
[Advert Ref: BFS:2843]
Price: All-inclusive franchise fee of $49,700 (about £36 800)
WSI is currently ranked as the # 1Internet Franchise, the #1 Overall Technology Franchise. WSI has established one of the most lucrative, proven, Franchise Opportunities in the world today!
Home based or office based
Complete Training and Support.
See Further Details
If you are looking to start a business in the next 6 months, then let us tell you more.
The WSI formula is simple: Successful Franchise Owners + Successful Clients
= Successful Franchise Opportunity.
Profit with a Proven System! Now available in the UK.
For your free information package & CD
Advertise your 'business for sale'
with us.
Thousands of buyers visit us each day looking to buy a business.
You have the opportunity to contact registered buyers for free or advertise to attract prospective buyers for very little cost.
More info on selling busineses...


text:
- Shopping Bag ( 0 items )
Restorative nursing is an essential part of reimbursement, compliance, and the quality of life of your residents. Improper care planning or unclear documentation can negatively impact resident care and your bottom line. Rely on this one resource for all your restorative care questions and needs.
The Long–Term Care Restorative Nursing Desk Reference is a new all–inclusive desk reference that describes the clinical aspects of restorative nursing in detail and provides a much–needed guide for nurses in a long–term care facility. This resource makes it easy to find instant answers to questions you may have about maintaining or developing your restorative program.
The Long–Term Care Restorative Nursing Desk Reference offers the help you need to create or sustain an effective restorative care program that puts your resident's needs first.
Chapter 1: Introduction to Restorative Nursing
Chapter 2: Legal Considerations
Chapter 3: The Restorative Team
Chapter 4: Establishing a Restorative Nursing Program
Chapter 5: Restorative Care and the Nursing Process
Chapter 6: Reimbursement Basics
Chapter 7: Restorative Meal Service and Dining
Chapter 8: Restorative Aspects of Elimination and Fluid Balance
Chapter 9: Restorative Approaches to Preventing Declines
Chapter 10: Basics of Bariatric Care
Chapter 11: Restorative Approaches to Fall Prevention, Behavior Management, and Restraint Elimination
Chapter 12: Restorative Exercises and Activities
Chapter 13: Restorative Documentation


text:
– Francesco Mitrano, Founder and President Monte-Carlo Polo Club –
Polo at the sparkling kingdom on the Cote d'Azur: It was no easy feat but Francesco Mitrano, Founder and President of the Monaco Polo Federation, found the perfect place for polo- a sumptuous private property just a few minutes drive from Monaco. Its first event, and third in the Monte Cup series, will be held during the first week of July 2015. The Monte Carlo Polo Federation is proud to announce that our event this year under the coveted patronage of S.A.S. Prince Albert II of Monaco, and included in the Principality's flagship event "2015: L'Année de la Russie".
The Monte Carlo Polo Federation strives to bring polo playing and international polo to Monaco. Our Club House, Riding School, and playing fields shall soon attest to this.
22. December 2014
27. November 2014
7. July 2014
30. June 2014
17. June 2014
13. December 2013
28. July 2013
After the successful debut tournament in summer of 2013 under the patronage of Monaco's Prince Albert II, the Monte-Carlo Polo Club opened its own polo school at the beginning of this year. Experienced players as well as newcomers can find the right coaches and appropriate training at the polo school.
– Francesco Mitrano, Founder and President Monte-Carlo Polo Club –
Our third international 10-goal tournament will be held from the 2nd to 5th of July 2015 at our newest venue: a private property located 10 minutes outside of Monaco. We will be opening with our customary Inauguration ceremonies and Polo Parade on the famous Place du Casino in Monte-Carlo before taking on 3 days of sports and luxury: Polo matches, Cocktails & Parties, our usual Hat Competition and a Charity Gala. In honour of Monaco's annual flagship event commemorating 150 years of cultural ties with Russia we will also be featuring artworks by prized Russian artists, and a fashion catwalk during our Gala by haute couture Russian designers. Any information, team, and sponsor requests can be made to email@example.com
La Martina is synonymous with and symbolic of polo. From its origins in Argentina 30 years ago La Martina now has over 75 shops worldwide supplying not only highly advanced polo equipment but also a highly sought after fashion range. La Martina is the official clothing and equipment suppliers for Monte-Carlo Polo Cup.


text:
Forgot Password? | Not a User? Sign up
Your browser does not support iframes.
It's time once again to get crabby in Little River.
The 34th annual Blue Crab Festival is set to get under way this weekend on the historic Little River, S.C., waterfront just across the state line.
Scheduled 9 a.m. to 6 p.m. Saturday and Sunday, May 16 and 17, the award-winning festival traditionally showcases all-day entertainment and an array of food, about 200 arts-and-crafts vendors, business booths and community groups lining the Little River waterfront the weekend after Mother's Day.
Flip-flops are totally acceptable and so is dancing.
Those are just two of the highlights at the fourth annual Flip Flop Ball to benefit Novant Health Foundation Brunswick Medical Center this coming Friday, May 15.
The ball launches with cocktails starting at 6:30 p.m. at the Brick Landing Plantation clubhouse, 1882 Goose Creek Road in Ocean Isle Beach, following by a casual, fun evening of dinner and dancing starting at 7 p.m.
Shirts are required, flip-flops are optional, but a beach attitude is a must, organizers say.
Sunset Beach police investigated the following incidents and made the following arrest. All information is taken directly from department reports.
April 25
Jaquelyn Rae Covell, 18, of 260 Maple Road, Maple, was charged with simple assault.
May 2
Breaking and entering, larceny of two iPads reported on Great Egret Circle.
Injury to real property reported on Avian Drive.
May 3
Assault on a female reported on Seaside Road.
CAROLINA SHORES — Town commissioners have given preliminary approval to the town's proposed 2015-16 budget and final approval on annexation and economic-incentive measures.
Action on these items came at the town board's monthly meeting last Thursday, May 7.
The town's $1,410,600 balanced budget for fiscal 2015-16 does not raise taxes or fees and in fact represents a 3 percent tax cut because of the drop in assessed values countywide, Town Administrator Jon Mendenhall noted in his monthly report.
Mediation between the town of Sunset Beach and developer of Jaguar's Lair has hit an impasse following a meeting last week.
Town Administrator Susan Parker issued a news release following the May 6 pre-litigation mediation session between members of the town's mediation team and representatives of Jaguar's Lair developer Coastal Companies.
SUNSET BEACH — A handful of residents had comments as town staff outlined details of a recommended $5,833,278 budget for fiscal 2015-16 calling for a 5½ cent tax rate increase.
Sunset Beach Finance Director Bonnie Schwerd presented an overview at Sunset Beach Town Council's monthly meeting Monday night.
The rate increase, if approved, will go up from 11½ cents to 16 cents per $100 of valuation.
Hunter Allen and Reid Love drove in three of East Carolina's seven runs on Senior Night, May 12, lifting the Pirates to a 7-0 win against Elon in seven innings at Lewis Field inside Clark-LeClair Stadium. The game was called early because of inclement weather in the area.
With the victory, the Pirates improve to 33-20. The Phoenix drop to 24-27. The victory pushed ECU's home record to 24-12.
Allen, a co-captain, led the Pirates' seven-hit attack, going 2-for-3 with two RBIs and a run scored. He has 15th multi-hit games this season.
After a year and a half of renovations, Town Creek Park has reopened.
The park upgrade, which began in October 2013, was intended to be a yearlong, $5.3 million project — if construction delays could be avoided.
Although weather delays extended the work by another half year, the project stayed on budget coming in at about $5.4 million, parks and recreation director Aaron Perkins said.
"Weather backed us up in the fall and winter. That was a big thing," he said.
OCEAN ISLE BEACH — Ocean Isle Beach residents will have the chance to speak on the proposed 2015-16 town budget at a June 9 meeting.
Town Administrator Daisy Ivey presented town board members with the budget at Tuesday's regular May meeting. The board voted unanimously, 5-0, to set the public hearing for the budget at 9 a.m. to open the June meeting.
The town staff has proposed a tax rate of .1875 per $100 valuation for fiscal year 2015-16.
Uber is an Internet taxi. It turns out I forgot to mention that the last time we spoke and it lead to some confusion.
I don't know why they didn't call it Internet Taxi or iTaxi or eTaxi and I can only assume they went with Uber because Qbert was taken.
I was too busy yapping about my trip to New York to fully flesh out a description of what an Uber is until now.
And now I'm going to yap about my trip some more.
No, not a trip. More of a pilgrimage.
Copyright © 2015
The Brunswick Beacon is your source for local news, sports, events and information in Brunswick County, North Carolina and surrounding areas.


text:
Photo by Romulo Yanes
Leave a Review
Absolutely delicious. It does certainly remind me of puddings that my grandmother made. I am a real strawberry fan, and upped the amount of strawberries to 2 cups.
Not exactly pudding soft, but delicious nonetheless. I suppose if you bake it for less than 30 min it would come out softer. However, for me, it was better well baked because it formed this delicious crust on top. yumm
This is a simple but delicious cake. Agree with the previous poster that rhubarb should be cut into very smal pieces. A really wonderful and simple spring dessert.
Easy and tasty. Cake is light yet buttery--a welcome contrast to the fruit. To avoid stringiness in rhubarb, slice into very small pieces. Tastes best fresh; cake gets a little rubbery the next day (although with the butter content, storing it in the refrigerator contributed to the denser second-day texture).
Oh my goodness! This was a hit for Mother's Day. Only thing different I would do next time is add cinnamon to the dry ingredients. Also would serve it warm from the oven with vanilla ice cream. DELICIOUS!
Made as written. This is incredibly easy to throw together, and I loved it. The only change I would make is to bake slightly longer. Despite the tester coming out clean, I didn't care for the pudding texture of the finished cake. I'll leave it till the cake is nice and firm next time, more like a cobbler. I'm unsure whether I'd add more fruit, as many reviewers have suggested. It might increase the soggyness (but the flavor of the fruit was wonderful!)
While I love the tartness of strawberry and rhubarb, I had forgotten that rhubarb is unpleasantly stringy, and so to me the texture of the filling really detracted from this recipe. If you're not bothered by that, you'll probably really like this.
This recipe was quick and easy to prepare and came out fabulous. :) I, like others, increased the fruit portion, but didn't increase the sugar. I will definitely make this one again
This was very good and got rave reviews at a potluck last night. I doubled the recipe for 13 X 9 glass baking dish. I also used frozen rhubarb, and about 3 cups strawberries for the double recipe. I did not have any trouble with the "drizzling" of fruit on top of the batter. Was good served warm with vanilla ice cream. Leftovers were claimed by the guests for breakfast the next day.
I used twice as much fruit (did NOT increase sugar, did increase cornstarch by 1/2 t) and skipped the cook the rhubarb for 3 min (I already mixed the fruit with it!). It came out beautifully! It will be made again, possibly with other fruit...peaches, apples, blackberries....


text:
Mon-Fri: 7am-1am EST / Sat-Sun: 7am-11pm EST
Below is a list of all parts for the Hotpoint Refrigerator CSC27HRBWH - Side-by-side. To find the repair part you need, you can browse the list below or you can narrow your choices by searching for a part by name or description.
This evaporator fan motor operates in a counter clockwise fashion. This motor's shaft is 3/8 of an inch and the motor has two right side terminals. NOTE: Harness wires NO longer comes with the part.
This motor is used to activate the blades to crush the ice for dispensing.
Lower door hinge cam riser for refrigerator/freezer - this is one of the parts needed if the door won't stay closed.
Size - 8-18 ab
This ice dispenser blade fits on to the back of the ice auger to help dispense ice.
All brand logos are trademarks of their respective owners.
The PartSelect logo is a Registered Trademark of Atlantic Laundry Centres, Ltd.
Copyright © 1999-2015 , Eldis Group Partnership. All rights reserved.


text:
Overview of content related to 'digitisation'
This page provides an overview of 1 article related to 'digitisation'. Note that filters may be applied to display a sub-set of articles in this category (see FAQs on filtering for usage tips). Select this link to remove all filters.
Digitising or digitisation is the representation of an object, image, sound, document or a signal (usually an analog signal) by a discrete set of its points or samples. The result is called digital representation or, more specifically, a digital image, for the object, and digital form, for the signal. Strictly speaking, digitizing means simply capturing an analog signal in digital form. For a document the term means to trace the document image or capture the "corners" where the lines end or change direction. (Excerpt from Wikipedia article: Digitisation)
Key statistics
Metadata related to 'digitisation' (as derived from all content tagged with this term):
See our 'digitisation' overview for more data and comparisons with other tags. For visualisations of metadata related to timelines, bands of recency, top authors, and and overall distribution of authors using this term, see our 'digitisation' usage charts.
Top authors
Ariadne contributors most frequently referring to 'digitisation':
Note: Links to all articles by authors listed above set filters to display articles by each author in the overview below. Select this link to remove all filters.
|Article summary
NetLab's Digital Library Gâteau
Jessica Lindholm reports from the conference "NetLab and friends: Tribute and outlook after 10 years of digital library development". The conference was held in Lund, Sweden 10-12 April 2002.
July 2002, issue32, feature article


text:
GQ's digital edition designed specially for your device
Only £1 an issue!
By Bill Prince 14 October 10
Unlike its buses, London's hotels make for a delightful place to rest and recuperate. But just like those public transport workhorses, a whole rush of new openings, restorations and welcome recalibrations are arriving all at once in and around the city this autumn...


text:
Activate Your Jeunesse
Account June 1!
If you are a MonaVie Distributor or Preferred Customer, you must activate your account with Jeunesse to place orders, adjust your AutoShip, and to start earning bonuses based on the Jeunesse Financial Rewards Plan.
What do you need to do get started with Jeunesse?
Step 1 – Activate your Jeunesse account. Go to the Jeunesse Back Office (Joffice™) login page: joffice.jeunesseglobal.com.
- Your username will be "MV_Current ID Number". (Ex: If your current MonaVie/mynt distributor ID is 1234 then your Jeunesse username will be "MV_1234".
- Your password will be the same password you have always used to log in to your MonaVie/mynt Virtual Office.
Step 2 – Carefully read and accept the necessary documents, including the Jeunesse Policies & Procedures.
Step 3 – Choose your new username to set up your personalized website. Your username will also serve as your unique Site URL for your personalized Jeunesse website, so please choose it carefully. (Ex: If your username is John117, your personalized website will be John117.jeunesseglobal.com). See FAQs under Virtual Office & Websites for more details.
Step 4 – Visit your Profile page and review the following:
- Select which leg you want to use for new enrollees under the Lock Placement section (See FAQs under Virtual Office & Websites).
- Select your language.
- Check your user information to be sure it is correct and up-to-date.
- Review and confirm your AutoShip information.
Step 5 – Watch the Jeunesse Training Videos (English only)
Will both MonaVie and mynt distributors transition fully to Jeunesse?
Worldwide, MonaVie distributors and mynt brand promoters will be transitioned fully to Jeunesse and become official Jeunesse Distributors. The business opportunity, back office, and all events in each market will be Jeunesse going forward.
MonaVie distributors and mynt brand promoters will have access to all of the Jeunesse products available in their respective market and many of the same MonaVie/mynt products after the transition.
Will I still be able to access my Virtual Office?
Yes, but please note that after 11:59 p.m. (US-MDT) on Friday, May 29, 2015 (end of bonus period 543), you will only be able to access historical reports for a period of at least 30 days. No business transactions (ordering or enrollments) will be allowed after Friday, May 29.
What will happen to my affiliate link and replicated websites?
After Friday, May 29, your affiliate links and your MonaVie or mynt replicated websites will no longer be available. You will receive a free Jeunesse personalized website that you will be able to send retail customers to for purchasing products—and you will receive credit for any sales placed on your personalized website. Your Preferred Customers will be able to log in to the Joffice and place orders there.
Does Jeunesse offer a free replicated website for my business?
Yes! By virtue of you activating your Jeunesse account, you will automatically receive a free Jeunesse personalized website. Through your personalized website you will be able to send people to your very own website, where customers can place orders and you can receive credit for the sale. You can also enroll new prospects.
Your Joffice username will also be your Site URL for your personalized website. (Ex: If your Joffice username is John117, your personalized website will be John117.jeunesseglobal.com). When you go to your Jeunesse personalized website through a web browser, you will be able to verify that it is indeed your website by checking the contact information in the upper right corner of the page.
Note: If you decide not to change your username at the time you activate your account with Jeunesse, you will have until August 1, 2015, to change your Username. Each time you log in to the Joffice, you will be prompted to change your username.
Will I still be able to access the mynt biz and TouchPoint apps?
No. These two apps will go away. If you have a subscription, your subscription will be transferred over to Jeunesse and you will be granted access to Jeunesse's app called Jmobile™.
What will happen to MonaVie and mynt websites?
After Friday, May 29, all MonaVie and mynt websites will go down and will be redirected to a landing page with information on the transition and how distributors or preferred customers can activate their account with Jeunesse.
Our three products sites, MonaVieJuices.com, COREin8.com, and EMVEnergy.com, will go down between Saturday, May 30, and Monday, June 1, for maintenance. When these sites become live again, you will be available to use these sites for product information purposes.
Which lock placement setting should I use for new enrollees in Jeunesse?
We advise you to change your lock placement (similar to Leg Preference) from its default automatic setting for better control over your genealogy tree. You can select which leg you want new enrollees to sign up under on your Profile page in Joffice. Be sure to click the Submit Changes button to save your changes to your Profile settings.
Please note: If your enrollee is on the wrong leg, you have up to 72 hours to contact Customer Service and request a placement change. Placement must be changed before the enrollee selects "Join Now."
How can I use inside placement in my Jeunesse genealogy tree?
You must achieve the rank of Qualified Sapphire or higher to use inside placement. After the transition, a team will do a clean-up of these inside legs, where possible, such that inside legs can be brought to the outside. There is no exact time-frame on when this will be complete, but we will keep you informed on the progress.
Please note: You must manually designate inside placement for each enrollee, as placement will revert to its default setting following each enrollment.
Where can I find marketing resources and other business tools?
Jeunesse provides a variety of tools to help you get your business booming. Download the Jmobile app from the App Store or Google Play to your smartphone or tablet for easy access to Jeunesse when you're on-the-go. Check out Jcloud™ under the Members Only tab in Joffice to download high-quality marketing resources such as videos and presentation materials.
Jeunesse Founders Bonus Pool
2% of the MonaVie/mynt global CV will be paid quarterly to members who purchase the Founder's Package. 1000 CV of Personal Group Volume (PGV) and Personal Volume (PV) = 1 share. The proceeds are divided evenly based on shares obtained by the Founder member. The value of the shares will vary from one trimester to the next, depending on the number of qualifying points vs. the total company CV sales for that quarter.
Incentive Travel Promotion
When will I receive my last bonus check from MonaVie?
|U.S. MonaVie
|June 5, 2015
|U.S. mynt
|June 8, 2015
|June 9, 2015
|June 15, 2015
|June 15, 2015
|All other international markets
|June 9, 2015
When will I receive my first bonus check with Jeunesse?
On June 1, you will begin accruing commissions according to the Jeunesse Financial Rewards Plan. Please note that Jeunesse's commission weeks run from Monday to Sunday.
Because of the Jeunesse commission payout delay, you will receive your first bonus check (if eligible) from Jeunesse on Monday, June 22, 2015.
Will I still be able to access my commissions through MVPay Hub? And, how will I receive new commission with Jeunesse?
Any new distributors you sign up after the transition will need to sign up for a Jeunesse wallet in the Jeunesse Back Office. Any new card requests will need to be directly made from the Jeunesse Back Office. Note that the Jeunesse card is a non-branded USD card and it could take up to 14 days for you to receive the card after your request is made.
What rank will I be when I transition to Jeunesse?
Your highest paid-as rank with Jeunesse will be based on your highest paid-as rank in the last 12 weeks for purposes of bonus level access as outlined in the Jeunesse Financial Rewards Plan. You will maintain this paid-as rank for a period of 3 months.
Below is a chart of your equivalent rank with Jeunesse.
|MonaVie Rank
|Jeunesse Rank
|Preferred Customer
|Preferred Customer
|Star 250
|Star 500
|Star 1000
|Sapphire Elite
|Blue Diamond
|Sapphire Elite
|Purple Diamond
|White Diamond
|Black Diamond
|Royal Black Diamond
|Presidential Black Diamond
|Double Diamond
|Imperial Black Diamond
|Double Diamond
|Crowne Black Diamond
|Double Diamond
|Double Black Diamond
|Double Diamond
|Triple Black Diamond
|Double Diamond
What MonaVie or mynt products will remain in each market?
The following MonaVie or mynt products will be available to purchase by only MonaVie distributors or mynt brand promoters who transition to Jeunesse, as well as to any new distributors or customers that former MonaVie distributors or mynt brand promoters enroll. In addition to these products, MonaVie distributors or mynt brand promoters who transition, and any new enrollees, will also have access to all Jeunesse products available in the respective market.
MonaVie Essential
MonaVie Active
MonaVie Pulse
MonaVie (M)mūn
MonaVie MX
Energy Drinks
EMV Acai
EMV Acerola
EMV Jabu
EMV Citrus Zero
CORE Products
HEALTH PRO SKUs
CORE Transformation Pack
CORE Turbo Start Pack
CORE IGNITE 4-Week Pack
CORE DETOX Pack
CORE Protein Shakes (Vanilla Bean & Double Chocolate)
CORE Boost Cleanse (U.S. only)
CORE Boost Burn (Ignite in Canada)
CORE Boost Build (U.S. only)
CORE Boost Pro-Bio
MonaVie Juices
MonaVie MX
Naara Beauty Drink
CORE Products
CORE Protein Shakes (Vanilla Bean & Double Chocolate)
CORE FPR Pre-Workout
CORE FPR Intra-Workout
CORE FPR Post-Workout
Energy Drinks
EMV Acai EMV Citrus Zero
Nutrition Shake Mix (Chocolate Berry)
Snack Bar (Berry)
MonaVie Juices
MonaVie MX
Energy Drink
(Peru only) EMV Acai
MonaVie Juices
MonaVie Original
MonaVie Active
MonaVie Protect (Pending full launching throughout Europe in September or Fall 2015)
MonaVie Juices
MonaVie Original
MonaVie Active
MonaVie Pulse
MonaVie (M)mūn
MonaVie MX
MonaVie Gels
MonaVie Original
MonaVie Active
MonaVie Pulse
MonaVie EMV
Energy Drinks
EMV Lite
MonaVie Essential
MonaVie Active
MonaVie Pulse
MonaVie MX
RVL Nutrition Shake Mix
RVL Multifiber Complete
MonaVie (M)mūn Powder
MonaVie Essential
MonaVie Pulse
RVL Nutrition Shake Mix
RVL Multifiber Complete
MonaVie (M)mūn Powder
MonaVie Essential
MonaVie Active
MonaVie Pulse
RVL Nutrition Shake Mix
RVL Multifiber Complete
MonaVie (M)mūn Powder
MonaVie Essential
MonaVie Active
MonaVie (M)mūn
MonaVie Essential
MonaVie Active
MonaVie Pulse
RVL Nutrition Shake Mix
RVL Multifiber Complete
MonaVie Original
MonaVie Active
MonaVie Pulse
Will product prices change?
What will happen to my Autoship?
What will happen with the CORE HEALTH PRO model?
We will continue to move forward with the CORE product line and the CORE HEALTH PRO bulk packages. This is good news! You can continue to move forward as a CORE HEALTH PRO after the transition. There may be minor modifications made to pricing to align with the Jeunesse business model and opportunity, but the program will remain intact.
What will happen to car programs?
Europe Car Program. We will continue to pay, based on last 4 week average, for people who have proof of a lease. We will continue to pay this bonus amount for an additional 12 weeks after the transition.
U.S. & Canada 4×4 Car Program. We will continue to pay for people who have proof of a lease. We will continue to pay this bonus amount for an additional 12 weeks after the transition.
U.S. & Canada 4×4 Bonus Program. Square and 4×4 bonus program will be discontinued. All bonuses earned by end of bonus period 543 (May 29, 2015) will be paid out on your last MonaVie bonus check.
How come I don't see my carry-forward volume?
What payment methods will go away?
- All markets: PayPal and Direct. (Note that this payment method will be available in the near future with Jeunesse.)
- U.S.: ACH payment
- Direct pay: All markets
- Brazil: Boleto
- Europe: PLN & HUF CC payments (only Euros and GBP) and reference deposits/bank transfers for AutoShip
- HK: WorldPay/CUP
- Japan: Bank transfers for AutoShip AND credit card via fax or email
- Malaysia: Infinitium CC payments
- Mexico: Only CC will remain
- Peru: ACH/Wire
- Korea: Bank transfer and bank transfer virtual account and credit card fax
- Taiwan: Bank transfer
Will I see any changes to shipping?
What distributor or customer support phone numbers do I use?
Support lines will not be available over the weekend while systems are down and being upgraded. Our support lines will open at the normal times on Monday, June 1. We understand that you will have questions over the weekend. Collect your questions and talk to your upline for further information. And, please be patient when calling in on Monday, June 1.
Phone: 1-866-217-8455
Outside the United States: +1-801-748-3110
Monday–Thursday: 8 a.m.– 6 p.m. (US-MDT)
Friday: 8 a.m.–midnight (US-MDT)
JNS Transition Training Videos & PDFs
Opportunity Overview
Maximizing the new Rewards Plan
Rewards Plan
Do you have additional questions?
Phone: 1-866-217-8455
Outside the United States: +1-801-748-3110
Monday–Thursday: 8 a.m.– 6 p.m. (US-MDT)
Friday: 8 a.m.–midnight (US-MDT)


text:
Video: Data on More Than 15 Novartis Oncology Compounds at ASCO Highlight Progress Toward Targeted Therapies for Diverse Tumor Types
– Oral presentation on Sandostatin(R) LAR Depot Phase III data shows significant antitumor benefit in patients with advanced neuroendocrine tumors of the midgut
– Early data show that at eight weeks of treatment, Afinitor(R) stabilized or reduced tumor size in 61% of patients with advanced liver cancer
– New data reveal postmenopausal women with breast cancer taking Femara(R) experience better cognitive function than those taking tamoxifen
– Phase II data show potential of Glivec(R) in treating patients with advanced KIT-mutated melanoma; other Novartis data on advanced melanoma also presented
To view the Multimedia News Release, go to: http://www.prnewswire.com/mnr/novartis/36143/
"Our strong presence at ASCO showcases our continued progress in developing innovative therapies for patients with cancer through our comprehensive discovery and development program," said
Sandostatin LAR in metastatic neuroendocrine midgut tumors
Data from the PROMID study (abstract #4508)* show Sandostatin(R) LAR Depot (octreotide acetate for injectable suspension) demonstrated a significant antitumor effect in patients with metastatic neuroendocrine tumors (NET) of the midgut(1).
Sandostatin LAR, when compared to placebo, more than doubled time without tumor growth (15.6 months vs. 5.9 months) and reduced the risk of disease progression by 67% (hazard ratio=0.33 with 95% confidence interval 0.19 to 0.55; P=0.000017)(1).
This important benefit was seen in patients with functioning tumors (i.e., tumors that are associated with carcinoid syndrome due to the secretion of various hormones that cause symptoms, such as diarrhea or flushing) and non-functioning (non-secreting) tumors. In an analysis of patients with non-functioning tumors, which affect the majority of people with NET, time to tumor progression for patients receiving Sandostatin LAR was 27.14 months versus 7.21 months for those on placebo (P=0.0008)(1).
Further, a statistically significant benefit was observed in patients with tumor load less than or equal to 10%, which suggests a potentially important role for treatment in the early stages of the disease. The median time to tumor progression was 27.1 months in the patients receiving Sandostatin LAR versus 7.2 months in the placebo group (P<0.0001)(1).
The trial, called PROMID (Placebo-controlled prospective Randomized study on the antiproliferative efficacy of Octreotide LAR in patients with metastatic neuroendocrine MIDgut tumors), is a Phase IIIb study conducted at 18 sites in
Neuroendocrine tumors originate from cells that have roles both in the endocrine and nervous systems. While these NET are often slow-growing, when the tumor is inoperable patients with advanced NET have limited treatment options(2).
The safety findings observed in the PROMID study were consistent with those seen in previous studies of Sandostatin LAR in patients with NET. The most frequently observed serious adverse events affected the gastrointestinal tract, hematopoietic system and other general symptoms such as fatigue and fever(1).
Afinitor in patients with advanced liver cancer
Phase I data (abstract #4587) demonstrated that 61% of patients with advanced hepatocellular carcinoma (HCC) who received daily treatment with Afinitor(R) (everolimus) tablets had tumors that stabilized or reduced in size(3).
There are currently a limited number of treatment options for patients with advanced HCC, the stage when most are diagnosed(4)(5). Everolimus shows potential to help address this unmet medical need(3).
The trial, conducted in
The Grade 3 and 4 adverse events reported in the study included elevated bilirubin, drop in platelets count, diarrhea, bleeding, cardiac ischemia, elevated liver function tests and infection. Reactivation of Hepatitis B virus was observed in four patients as well as reactivation of Hepatitis C virus in one patient(3).
Based on these data, a global Phase III clinical trial to study the daily everolimus regimen in patients with advanced HCC is in development by Novartis.
Femara BIG 1-98 data on cognitive function
Impaired cognition is a concern among breast cancer patients taking hormonal therapies. Estrogen is believed to have a direct influence on cognitive function. Aromatase inhibitors reduce the level of circulating estrogen in the body. It has been suggested that reduced estrogen in the body is linked to a decline in cognitive function(6).
A new substudy (abstract #510) conducted within a subgroup of patients enrolled in the independent Breast International Group (BIG) 1-98 study (Femara(R) [letrozole tablets] vs. tamoxifen) found that postmenopausal women with hormone receptor-positive early breast cancer taking adjuvant Femara had better overall cognitive function than those taking tamoxifen, based on validated scales of cognitive function collected at the fifth year of endocrine treatment(6).
Results from this study revealed that the group of patients receiving Femara had clinically and significantly better overall cognitive function than the patients in the tamoxifen group (difference in mean composite scores =0.23, P=0.04, 95% confidence interval: 0.02-0.54). Overall, both groups performed below age norms on most domains(6).
Highlights in melanoma
New data highlight the potential of two Novartis products as treatments for advanced melanoma, the most serious form of skin cancer. Melanoma accounts for 41,000 deaths worldwide each year(7)(8). While melanoma is curable when diagnosed and treated in early stages, advanced melanoma is often resistant to currently available treatments(9).
New data from a Phase II study (abstract #9001) show the potential of Gleevec(R)(#) (imatinib mesylate) in treating patients with advanced melanoma harboring KIT mutations. A mutation in the protein called KIT, located on the surface of normal cells, signals cells to continually grow and divide. Similar KIT mutations in GIST were shown to be treated effectively by Gleevec. The preliminary data from the investigator-driven study show that five out of five patients evaluable for responses showed either partial responses to Gleevec (3 out of 5) or stable disease (2 out of 5). Responses in two of the three patients are ongoing past 18 weeks. These favorable results have allowed the study to continue to a second expanded stage of enrollment(10).
Other data on advanced melanoma include preliminary results from a Phase II trial (abstract #9027) that show 72% of patients (20 out of 28) with advanced melanoma treated with everolimus in combination with bevacizumab experienced a clinical benefit (4% had a partial response and 68% had stable disease). The combination of everolimus and bevacizumab was generally well tolerated. According to the abstract, one patient withdrew from the trial due to interstitial pneumonitis, which was reversible, and one patient had a fatal heart attack, possibly bevacizumab-related. Grade 3 mucositis occurred in 13% of patients and all other grade 3 toxicities occurred in <10% of patients(11).
Early stage development data
Abstract #8542: Panobinostat + lenalidomide and dexamethasone Phase I trial in multiple myeloma (MM)
- In this first Phase I clinical trial assessing the combination of panobinostat (LBH589) in combination with lenalidomide and dexamethasone, the 5 mg and 10 mg doses of panobinostat were safe when administered to patients with multiple myeloma(12).
Abstract #3563: TKI258 (dovitinib lactate) in metastatic renal cell carcinoma (mRCC) patients refractory to approved targeted therapies: a Phase I/II dose finding and biomarker study
- This study of heavily pre-treated metastatic renal cell carcinoma patients demonstrated that TKI258 500 mg/day may be an appropriate dosing schedule and showed clinical benefit in this patient population(13).
Abstract #3533: Pharmacodynamics and pharmacokinetics of AUY922 in a Phase I study of solid tumor patients
- These data support the use of HSP70 as a biomarker for HSP90 inhibition. Inhibition of HSP90, a key target that regulates tumor cell survival and division, through the use of AUY922, resulted in an up regulation/increase of HSP70. The change in HSP70 observed at the highest dose of AUY922 exceeded the level needed to inhibit tumor growth in a mouse model for breast cancer(14).
About the Novartis Oncology pipeline
The Novartis Oncology pipeline features 18 new molecular entities. These compounds are being studied in more than 40 different cancer types in approximately 15,000 patients. The pipeline portfolio encompasses a broad array of therapeutic strategies for fighting cancer, including novel targeted agents, monoclonal antibodies, deacetylase (DAC) inhibitors, multiligand somatostatin analogs and novel cytotoxics.
Sandostatin LAR important safety information
Sandostatin LAR is a long-acting, injectable depot formulation of octreotide acetate, that is approved for the treatment of acromegaly, diarrhea/flushing episodes associated with advanced carcinoid tumors and profuse watery diarrhea associated with VIP-secreting tumors. Based on these attributes, octreotide has been used to treat symptoms associated with metastatic carcinoid tumors (flushing and diarrhea) and vasoactive intestinal peptide (VIP) secreting adenomas (watery diarrhea). In addition, octreotide substantially reduces and in many cases can control growth hormone and/or normalize IGF-1 levels in patients with acromegaly, a disease caused by a GH-secreting pituitary adenoma. Sandostatin LAR is not indicated as a treatment for tumor control. The clinical trials that supported approval of Sandostatin LAR did not study effect on tumor size or rate of growth.
The most frequently reported drug-related adverse events were biliary disorders (62%), gastrointestinal disorders (14% to 38%), and injection-site pain (20% to 50%). Hypoglycemia (4%), hyperglycemia (27%), sinus bradycardia (19%), conduction abnormalities (9%), and arrhythmias (3%) have been reported. Additional adverse reactions identified in clinical studies include nausea, abdominal pain, gas, constipation, vomiting, pain on injection, high or low blood sugar levels and slow or irregular heart rate. Many patients developed gallstones, although few patients required treatment.
For full prescribing information, please visit www.us.sandostatin.com.
Afinitor important safety information
Afinitor is approved in the US as the first oral, daily therapy (5 mg and 10 mg tablets) to treat patients with advanced renal cell carcinoma after failure of treatment with sunitinib or sorafenib. Afinitor is contraindicated in patients with hypersensitivity to everolimus, to other rapamycin derivatives or to any of the excipients. Potentially serious adverse reactions include non-infectious pneumonitis and infections for which patients should be monitored carefully and treated as needed. In addition, non-infectious pneumonitis may require temporary dose reduction and/or interruption or discontinuation. Patients with systemic invasive fungal infections should not receive Afinitor. Oral ulceration is a common side effect with Afinitor. Renal function, blood glucose, lipids and hematological parameters should be evaluated prior to the start of therapy with Afinitor and periodically thereafter. Strong or moderate CYP3A4 or P-glycoprotein inhibitors should be avoided. An increase in the dose of Afinitor is recommended when co-administered with a strong CYP3A4 inducer. Live vaccinations and close contact with those who have received live vaccines should be avoided by patients taking Afinitor. Afinitor should not be used in patients with severe hepatic impairment. Afinitor may cause fetal harm in pregnant women.
The most common adverse reactions irrespective of causality (incidence greater than or equal to 30%) were stomatitis, infections, asthenia, fatigue, cough and diarrhea. The most common grade 3/4 adverse reactions irrespective of causality (incidence greater than or equal to 3%) were infections, dyspnea, fatigue, stomatitis, dehydration, pneumonitis, abdominal pain and asthenia. The most common laboratory abnormalities (incidence greater than or equal to 50%) were anemia, hypercholesterolemia, hypertriglyceridemia, hyperglycemia, lymphopenia and increased creatinine. The most common grade 3/4 laboratory abnormalities (incidence greater than or equal to 3%) were lymphopenia, hyperglycemia, anemia, hypophosphatemia and hypercholesterolemia. Deaths due to acute respiratory failure (0.7%), infection (0.7%) and acute renal failure (0.4%) were observed in patients receiving Afinitor.
Femara important safety information
You should not take Femara if you are premenopausal. Your doctor should discuss the need for adequate birth control if you have the potential to become pregnant, if you are not sure of your postmenopausal status, or if you recently became postmenopausal. Femara is only indicated in postmenopausal women. Talk to your doctor if you're allergic to Femara or any of its ingredients. You should not take Femara if you are pregnant as it may cause fetal harm. Some women reported fatigue and dizziness with Femara. Until you know how it affects you, use caution before driving or operating machinery. Some patients taking Femara had an increase in cholesterol. Additional follow-up is needed to determine the risk of bone fracture associated with long-term use of Femara.
In the adjuvant setting, commonly reported side effects are generally mild to moderate. The most common side effects seen with Femara include hot flashes, joint pain, night sweats, weight gain, nausea, tiredness, other heart-related events and bone fractures. Other less commonly reported side effects include vaginal bleeding, blood clots, other cancers, osteoporosis, stroke, heart attack and endometrial cancer.
In the extended adjuvant setting, commonly reported side effects are generally mild to moderate. Commonly reported side effects for Femara include hot flashes, fatigue, joint pain, headache, increase in sweating, swelling due to fluid retention, increase in cholesterol, dizziness, constipation, nausea, cardiovascular ischemic events, muscle pain, osteoporosis, arthritis and bone fracture.
In the metastatic cancer setting, commonly reported side effects are generally mild to moderate and may include bone pain, hot flashes, back pain, nausea, joint pain, shortness of breath, tiredness, coughing, constipation, limb pain, chest pain and headache.
Gleevec important safety information
Fetal harm can occur when administered to a pregnant woman; therefore, women of childbearing potential should be advised to not become pregnant while taking Gleevec tablets and to avoid breast-feeding while taking Gleevec tablets because of the potential for serious adverse reactions in nursing infants. Sexually active female patients taking Gleevec should use adequate contraception. If the patient does become pregnant while taking Gleevec, the patient should be advised of the potential hazard to the fetus.
In adult Ph+ CML patients, severe (NCI Grades 3/4) lab abnormalities-including neutropenia (3.6%-48%), anemia (1%-42%), thrombocytopenia (<1%-33%), and hepatotoxicity (approx 5%)–and severe adverse experiences (NCI Grades 3/4), including severe fluid retention (e.g., pleural effusion, pulmonary edema, and ascites) and superficial edema (1.3%-11%), hemorrhage (1.8%-19%), and musculoskeletal pain (2%-9%) were reported among patients receiving Gleevec*. Severe fluid retention appears to be dose-related, was more common in the advanced-phase studies (where the dosage was 600 mg/day), and is more common in the elderly.
In HES/CEL patients, instances of Grade 3 leukopenia, neutropenia, lymphopenia, and anemia were reported.
For DFSP, severe (NCI Grades 3/4) lab abnormalities included anemia (17%), thrombocytopenia (17%), neutropenia (8%), and increased creatinine (8%).
In GIST, severe (NCI Grades 3/4) lab abnormalities (400 mg/day; 600 mg/day)–including neutropenia (10%; 11%), anemia (3%; 9%), thrombocytopenia (0%; 1%), and hepatotoxicity (6%; 8%)–and severe adverse experiences (NCI Grades 3/4), including severe fluid retention (eg, pleural effusion or ascites; 3%; 8%) and superficial edema (6%; 5%), hemorrhage (6%; 11%), abdominal pain (11%; 4%), nausea (6%; 4%), diarrhea (3%; 7%), and musculoskeletal pain (6%; 1%) were reported among patients receiving Gleevec.
Severe congestive heart failure and left ventricular dysfunction have occasionally been reported. Most of the patients with reported cardiac events have had other comorbidities and risk factors, including advanced age and previous medical history of cardiac disease. Patients with cardiac disease or risk factors for cardiac failure should be monitored carefully, and any patient with signs or symptoms consistent with cardiac failure should be evaluated and treated.
Dose adjustments may be necessary due to hepatotoxicity, other nonhematologic adverse reactions, or hematologic adverse reactions. Therapy with Gleevec was discontinued for drug-related adverse reactions in 2.4% to 5% of adult patients with Ph+ CML and for adverse reactions in 5% of KIT+ GIST patients. None of the 5 patients in the ASM study discontinued Gleevec due to drug-related events or abnormal laboratory values. Complete blood counts should be performed weekly for the first month, biweekly for the second month, and periodically thereafter as clinically indicated (for example, every 2-3 months).
A 25% decrease in the recommended dose should be used for patients with severe hepatic impairment.
Some GIST patients (5%) were reported to have severe gastrointestinal (GI) bleeds and/or intratumoral bleeds. GI tumor sites may have been the source of GI bleeds.
Patients should be weighed and monitored regularly for signs and symptoms of edema, which can be serious or life-threatening. There have also been reports, including fatalities, of cardiac tamponade, cerebral edema, increased intracranial pressure, papilledema, and GI perforation.
In patients with HES and cardiac involvement, cases of cardiogenic shock/left ventricular dysfunction have been associated with the initiation of imatinib therapy. The condition was reported to be reversible with the administration of systemic steroids, circulatory support measures, and temporarily withholding imatinib. MDS/MPD disease and systemic mastocytosis may be associated with high eosinophil levels. Performance of an echocardiogram and determination of serum troponin should therefore be considered in patients with HES/CEL, and in patients with MDS/MPD or ASM associated with high eosinophil levels. If either is abnormal, the prophylactic use of systemic steroids (1-2 mg/kg) for 1-2 weeks concomitantly with imatinib should be considered at the initiation of therapy.
Bullous dermatologic reactions (eg, erythema multiforme and Stevens-Johnson syndrome) have also been reported. In some cases, the reaction recurred upon rechallenge. Several postmarketing reports describe patients able to tolerate the reintroduction of Gleevec at a lower dose with or without concomitant corticosteroids or antihistamines following resolution or improvement of the bullous reaction.
Consider potential toxicities-specifically liver, kidney, and cardiac toxicity, and immunosuppression from long-term use.
Gleevec is metabolized by the CYP3A4 isoenzyme and is an inhibitor of CYP3A4, CYP2D6, and CYP2C9. Dosage of Gleevec should increase by at least 50%, and clinical response should be carefully monitored, in patients receiving Gleevec with a potent CYP3A4 inducer such as rifampin or phenytoin. Examples of commonly used drugs that may significantly interact with Gleevec include ketoconazole, acetaminophen, warfarin, erythromycin, and phenytoin. (Please see full Prescribing Information for other potential drug interactions).
For daily dosing of 800 mg and above, dosing should be accomplished using the 400 mg tablets to reduce exposure to iron.
Common side effects of Gleevec tablets
The majority of adult Ph+ CML patients who received Gleevec in clinical studies experienced adverse reactions at some time, but most were mild to moderate in severity. The most frequently reported adverse reactions (all Grades) were superficial edema (60%-74%), nausea (50%-73%), muscle cramps (28%-62%), vomiting (23%-58%), diarrhea (43%-57%), musculoskeletal pain (38%-49%), and rash and related terms (36%-47%).*(+)
The adverse reactions and safety profile for Ph+ ALL, MDS/MPD, ASM, and HES/CEL were generally similar to the safety profile for Ph+ CML.
The most frequently reported drug-related adverse reactions reported in the Ph+ ALL studies were mild nausea, vomiting, diarrhea, myalgia, muscle cramps, and rash, which were easily manageable. Superficial edemas were also a common finding in all studies and were described primarily as periorbital or lower-limb edemas. However, these edemas were rarely severe and may be managed with diuretics, other supportive measures, or in some patients by reducing the dose of Gleevec.
Frequently reported adverse reactions (all Grades) in the seven MDS/MPD patients assessed were nausea (57%); diarrhea and muscle cramps (43% each); anemia, fatigue, arthralgia, and periorbital edema (29% each).
All ASM patients experienced at least one adverse reaction at some time. The most frequently reported adverse reactions were diarrhea, nausea, ascites, muscle cramps, dyspnea, fatigue, peripheral edema, anemia, pruritus, rash, and lower respiratory tract infection.
All HES/CEL patients experienced at least one adverse reaction, the most common being gastrointestinal, cutaneous, and musculoskeletal disorders. Hematologic abnormalities were also frequent, with instances of Grade 3 leukopenia, neutropenia, lymphopenia, and anemia.
Frequently reported adverse reactions (all Grades) in the 12 DFSP patients assessed included nausea and fatigue (42% each); periorbital, peripheral and eye edema (33% each); diarrhea, vomiting, rash, lacrimation increased, and anemia (25% each); face edema, pyrexia, exertional dyspnea, rhinitis, and anorexia (17% each).
The majority of patients who received Gleevec in the GIST study experienced adverse reactions at some time. Most adverse reactions were mild to moderate in severity. The most frequently reported adverse reactions (400 mg/day; 600 mg/day) (all Grades) were superficial edema (81%; 77%), nausea (63%; 74%), muscle cramps (47%; 58%), diarrhea (59%; 70%), fatigue (48%; 53%), abdominal pain (40%; 37%), rash and related terms (38%; 53%), vomiting (38%; 35%), musculoskeletal pain (37%; 30%), and hemorrhage (26%; 34%).(+)
Supportive care may help management of some mild-to-moderate adverse reactions so that the prescribed dose can be maintained whenever possible. However, in some cases, either a dose reduction or interruption of treatment with Gleevec may be necessary.
Gleevec tablets should be taken with food and a large glass of water to minimize GI irritation. Gleevec tablets should not be taken with grapefruit juice and other foods known to inhibit CYP3A4.
Patients should be informed to take Gleevec exactly as prescribed, not to change their dose or stop taking Gleevec unless they are told to do so by their doctor. If patients miss a dose, they should be advised to take their dose as soon as possible unless it is almost time for their next dose, in which case the missed dose should not be taken. A double dose should not be taken to make up for any missed dose.
* Numbers indicate the range of percentages in 4 studies among adult patients with Ph+ CML in blast crisis, accelerated phase, and chronic phase.
(+) For more detailed study information, please see full Prescribing Information.
The foregoing release contains forward-looking statements that can be identified by terminology such as "progress toward," "potential," "will," "look forward to," "risk," "suggests," "potentially," "in development," "may," "pipeline," "being studied," "strategies," or similar expressions, or by express or implied discussions regarding potential future marketing approvals for compounds in development, potential new indications or labeling for existing products, or regarding potential future revenues from such compounds or products. You should not place undue reliance on these statements. Such forward-looking statements reflect the current views of management regarding future events, and involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no guarantee that any such development compounds will be approved for sale in any market. Nor can there be any guarantee that any of the existing products referred to in this release will be approved for any additional indications or labeling in any market. Neither can there be any guarantee that any of these compounds or products will achieve any particular levels of revenue in the future. In particular, management's expectations regarding compounds and products could be affected by, among other things, unexpected clinical trial results, including unexpected new clinical data and unexpected additional analysis of existing clinical data; unexpected regulatory actions or delays or government regulation generally; the company's ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry and general public pricing pressures; the impact that the foregoing factors could have on the values attributed to the Novartis Group's assets and liabilities as recorded in the Group's consolidated balance sheet, and other risks and factors referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated, believed, estimated or expected. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.
About Novartis
Located in
- Arnold R, et al. Placebo-controlled, double-blind, prospective, randomized study of the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: A report from the PROMID study group. Abstract # 4508. American Society of Clinical Oncology 2009 Annual Meeting,
Orlando, FL.
- Kloppel G, Perren A, Heitz PU The Gastroenteropancreatic Neuroendocrine Cell System and Its Tumors: The WHO Classification. Ann. of the New York Acad of Sci. 2006 Jan 16 2005;1014:13-27.
- Chen L, et al. Randomized, phase I, and pharmacokinetic (PK) study of RAD001, an mTOR inhibitor, in patients (pts) with advanced hepatocellular carcinoma (HCC). Abstract # 4587. American Society of Clinical Oncology 2009 Annual Meeting,
Orlando, FL.Abstract #510. American Society of Clinical Oncology 2009 Annual Meeting, Orlando, FL.
- American Cancer Society. How is Liver Cancer Treated? Available at: http://www.cancer.org/docroot/CRI/content/CRI_2_2_4X_How_Is_Liver_Cancer_Treated_25.asp?rnav=cri. Accessed
April 2009.
- American Cancer Society. How is Liver Cancer Staged? Available at: http://www.cancer.org/docroot/CRI/content/CRI_2_4_3X_How_is_liver_cancer_staged_25.asp. Accessed
May 2009.
- Ribi K, et al. Cognitive function in postmenopausal women receiving adjuvant letrozole or tamoxifen in the Breast International Group (BIG) 1-98 trial. Abstract # 510. American Society of Clinical Oncology 2009 Annual Meeting,
Orlando, FL.
- Skin Cancer Foundation. Understanding Melanoma. Available at: http://www.skincancer.org/melanoma/. Accessed
May 2009.
D. Max Parkin, MD et al. Global Cancer Statistics 2002. American Cancer Society. Available at: http://caonline.amcancersoc.org/cgi/reprint/55/2/74. Accessed May 21, 2009
- National Cancer institute. Recurrent Melanoma. Available at: http://www.cancer.gov/cancertopics/pdq/treatment/melanoma/HealthProfessional/page11. Accessed
May 2009.
- Carvajal RD, et al. A phase II study of Imatinib mesylate (IM) for patients with advanced melanoma harboring somatic alterations of KIT. Abstract # 9001. American Society of Clinical Oncology 2009 Annual Meeting,
Orlando, FL.
- Hainsworth J et al. Phase II trial of bevacizumab and everolimus in the treatment of patients with metastatic melanoma: Preliminary results. Abstract # 9027. American Society of Clinical Oncology 2009 Annual Meeting,
Orlando, FL.
- Spencer A, et al. Panobinostat + lenalidomide and dexamethasone Phase I trial in multiple myeloma (MM). Abstract #8542. American Society of Clinical Oncology 2009 Annual Meeting,
Orlando, FL.
- Angevin E, et al. TKI258 (dovitinib lactate) in metastatic renal cell carcinoma (mRCC) patients refractory to approved targeted therapies: a phase I/II dose finding and biomarker study. Abstract #3563. American Society of Clinical Oncology 2009 Annual Meeting,
Orlando, FL.
- Ide S, et al. Pharmacodynamics and pharmacokinetics of AUY922 in a phase I study of solid tumor patients. Abstract #3533. American Society of Clinical Oncology 2009 Annual Meeting,
Orlando, FL.
Novartis Oncology Media only: Megan Humphrey Novartis Oncology P: +1 862 778 6724 Dana Kahn Cooper P: +1 732 817 1800 F: +1 732 817 1834 e-mail: firstname.lastname@example.com Investors only: Richard Jarvis Novartis Corporation P: +1 212 830 2433 e-mail: email@example.com
(#) Known as Glivec (imatinib) outside the US,
(*) Updated data from all abstracts may be presented at the ASCO annual meeting
SOURCE Novartis Pharmaceuticals Corporation


text:
Fire rating drop great news for some county residents
We congratulate those residents in the county's central fire district who will benefit — financially as well as safety-wise — by the improved fire rating for an extended area, and we applaud all those who helped make the extension of the district possible. (November 19, 2014, Page 4A)
Letters to the Editor
Jeff Roy and Ottis Anderson write to express thanks on behalf of the Lafayette County Fire Department for those who've made the fundraising campaign a success, while Jesse Wright writes to say that the Board of Supervisors' vote to withdraw funding from the Yoknapatawpha Arts Council is a blow against future projects in the community. (October 7, 2011, Page 4A)


text:
Change edition
Remember me on this computer
Sign in
"Remember me" uses a cookie. View our Cookie Policy.
June 28, 2007 3:00 am
By Gerrit Wiesmann in Frankfurt and Andrew Edgecliffe-Johnson,in London
You have viewed your allowance of free articles. If you wish to view more, click the button below.
Printed from: http://www.ft.com/cms/s/0/e4666786-2514-11dc-bf47-000b5df10621.html
Print a single copy of this article for personal use. Contact us if you wish to print more to
distribute to others.
© The Financial Times Ltd 2015 FT
and 'Financial Times' are trademarks of The Financial Times Ltd.
Privacy policy |
Terms |


text:
Intelligent people that lack military power have done these things for years. If you don't have any real political and military power then you fight back using any means necessary. This is only the beginning.
In their eyes people that live in luxury while their military kills their relatives are no innocent people.


text:
Please enter a list name
You entered an invalid character [!@#$%^&*()_+-{};"]. Please enter a valid alpha numeric character.
Please name your Essential List:
You may add a description of the list:
Please name your Wish List:
Carol M. Bast is currently an Associate Professor at the University of Central Florida and a member of The Florida Bar, the Orange County Bar Association and the Academy of Legal Studies in Business. Ms. Bast is a member of many professional organizations, including American Society of Writers on Legal Subjects and the Legal Writing Institute. She has won several professional awards, presented at numerous events and co-authored several publications, including FOUNDATIONS OF LEGAL RESEARCH AND WRITING AND FLORIDA COURTS. Carol M. Bast is a graduate of New York Law School and received a Masters in Business Administration from the University of Central Florida and a Doctoral Degree in Spanish from the University of Florida.
Ransford C. Pyle is retired as Associate Professor Emeritus from the University of Central Florida and resides in Gainesville, Florida. In addition to FOUNDATIONS OF LAW: CASES, COMMENTARY AND ETHICS, he has authored several publications, including FAMILY LAW and BUSH V. GORE: UNDERSTANDING THE AMERICAN LEGAL SYSTEM. Dr. Pyle is a graduate of the University of Florida College of Law and received a Doctoral Degree in Anthropology from the University of Florida.
Our reader reviews allow you to share your comments on titles you liked,
or didn't, with others. By submitting an online review, you are representing to
Barnes & Noble.com that all information contained in your review is original
and accurate in all respects, and that the submission of such content by you
and the posting of such content by Barnes & Noble.com does not and will not
violate the rights of any third party. Please follow the rules below to help
ensure that your review can be posted.
We highly value and respect everyone's opinion concerning the titles we offer.
However, we cannot allow persons under the age of 13 to have accounts at BN.com or
to post customer reviews. Please see our Terms of Use for more details.
Please do not write about reviews, commentary, or information posted on the product page. If you see any errors in the
information on the product page, please send us an email.
Your Pen Name is your unique identity on BN.com. It will appear on the reviews you write and other website activities.
Your Pen Name cannot be edited, changed or deleted once submitted.
We're sorry, but penname is already taken.
penname is available!
By visiting the BN.com website or marking a purchase on BN.com, a User is deemed to have accepted the
Terms of Use.
Use Pen Name
Find a Different Pen Name
Welcome, penname
You have successfully created your Pen Name. Start enjoying the benefits of the BN.com Community today.


text:
Room was clean
Stairs were dirty. Hair dryer did not work.
Good location, staff was great, room was clean.
Walls are to thin could hear everything the people in the next room was talking about. The power went out so had to use phone light to do everything, if I didn't have the light it would have been bad..
The room was comfortable and the heater did a good job. The shower was good, but I missed the seat that I have in my shower at home. The complementary breakfast was surprisingly good. The staff was very friendly and courteous. Price was right.
Professional, very comfortable atmosphere. Great breakfast, excellent beds, newer remodel.
Hard to get to
ecomomy hotel worked for our needs
Here's why:
We're not the seller
At KAYAK we don't set prices, so it's not possible for us to guarantee what other companies are selling.
We aggregate tons of data for you
Our service lets you quickly and easily compare results from hundreds of travel sites at once. In this sense, KAYAK is a search engine and we don't guarantee prices we find.
Why aren't prices accurate 100% of the time?
Prices on airline seats, hotel rooms and car rentals can change frequently. Several people may also be trying to buy the same travel option simultaneously. As a result, you may find on occasion that certain prices are no longer available.
More questions or if you have a bad price to report to us
Please send us an
and someone from our team will get back to you promptly.
KAYAK is part of The Priceline Group, the world leader in online travel & related services.


text:
Airplane, Cairo
25 Reviews
25 Reviews
At Cairo Airport, once you have been through immigration and then customs. Go out into the main hall, and turn right to get to the taxi stands.
We paid a fixed price of LE42 (USD 7) which was cheaper than the price quoted in the Lonely Planet (it said USD 12).
The man at the taxi stand will quote you the fixed price (depending on what district you want to go to), you pay him, then get a receipt with the address and price on it.
Then you get taken down to the car park where the taxis are.
The driver will probably ask you for baksheesh once he safely delivers you to your desired destination.
When you arrive at Cairo International Airport, you'll most likely have to take a tram to the actual terminal. This gives you an excellent opportunity to take a picture of your first steps in Egypt! So, have your camera ready when you get off the plane!
I took Gulf Air from Hong Kong to Cairo. 10 hours from Hong Kong to Abu Dhabi (stop over Bangkok). Sleep one nite in Abu Dhabi, then catch another flight to Cairo, another 3.5 hour.
Have not been flying with Gulf air for 9 years, suprisingly they have improved a lot in the service. They now provide different languages speaking crews on flight. And the BEST part was that they put me to BUSINESS CLASS!!! That make my 10 hours so much easier!!!
We took the comfortable Oman Air flight from Delhi International Terminal no 3 in the mornig to Muscat, from there after 3 hours transit period we took another Oman Air filght to Cairo International airport. The flight time from New Delhi to Muscat is 3 hrs for a distance of 1987 KMs. It flew over Karachi, Pakistan and gulf of Oman. They served very good breakfast during the flight.
The flight from Muscat to Cairo was for 4.15 hours for a distance 2900KMs. They served good meal during the flight.
I flew Gulf air from Singapore to Bahrain (8 hours) with stopover and then from Bahrain to Cairo (3 hours) for this trip to Egypt.
Gulf air is the second after, Emirates airlines, from Middle East that I have flown. I found the services is minimal in the Economy class and the food on board are quite undesirable. I flew Emirates twice before (one Syria and the other to Morocco) and I found meals served in Emirates airlines are much better. The seating are smaller in Gulf air, in my opinion. No wet towel is served throughout the whole flight. All passengers have to use dirty hands to touch the bread (which is dry and cold). The meals are simple and tasteless. Look at the meal pics and see if that is the kind of in-flight meal you want. Sigh. This is not the airline I want to fly again unless I have no choice. Rating for food and general services: Poor
For citizens of the European Union, and probably quite a few other countries in the world, you don't really need a visa to enter Egypt. However, you need to buy visa stamps when you arrive at the airport. It will cost you 15 US dollars and they will only accept that currency, not the Egyptain pound. The British Foreign Office web site claims they also accept British pounds but my own experience is that it is not necessarilly the case and anyway it is much easier if you have USD.
So, make sure you have some US cash with you. Taxis from the airport might even ask you to pay in US dollars to get you to the town.
In many ways, Egypt travel becomes cheaper with a package deal which includes airfare plus internal transport plus hotel with breakfast while travelling in two. But now a days, cheap airline also operating to Cairo on a regular basis which can offer a price as low as one-third of the regular full price when booking online. Maerskair from Copenhagen have special deals in January and I paid only DKK 900 for a return ticket including taxes and charges.
To and from Cairo, oh I'd definitely recommend the aerial route, unless you find yourself a nice little cruise across the Med from Europe to Alexandria, and then a comfortable ground-transit down from there...but be verrrry careful when your BA flight is taxiing around the Cairo airport tarmac here before dropping you off back in London and you get that urge to take photos out the window...shhhhh! *they* don't like it when you do that...soooo, just dont tell *them* you're doing it...
Cairo International Airport is the major civilian airport in Cairo, Egypt. It is the primary hub for EgyptAir. It is located to the northeast of Cairo, about 15 km from the downtown area. It is administered by the Cairo Airport Authority. A free shuttle bus links the two terminals, 3km (1.9 miles) apart. The bus runs 24 hours a day and departs approximately every 30 minutes.
The Airport is connected to the city by two roads, the main access road is the Salah Salem Road that goes through Heliopolis from downtown and another secondary road, the Autostrad road.
A new established Shuttle Bus service that reaches to several distinations such as Heliopolis: Nasr City, Downtown Cairo, Giza, Mohandesin, Zamalek, Maadi, Haram (Pyramids area).
Taxis are available at any time, and operated on a flat fee basis. Official Cairo taxis are predominantly black and white. The Airport Bus Service both air-conditioned & non air-conditioned operates from Terminal 1. There are several stop bus stations; at Tahrir Square, downtown Cairo, Mohandesin, and along Pyramids Road in Giza . Entering the airport requires payment of a toll of 5 LE/3 hours for private cars and cabs.
There is a huge price discrimination on Egyptair domestic flights in Egypt. It is extremely cheap for locals and residents and extremely expensive for foreigners...
Here is an example:
I called the Egyptair office in Istanbul for a return ticket between Cairo and Sharm and was quoted 103 Euros return. I thought it was an OK deal so decided to buy once I was in Cairo. When I went to their office at the airport, I was quoted 165 Euros for the same ticket...
My Egyptair flight attendant friend told me that the tickets are cheaper outside Egypt to attract tourists. And once you are actually in Egypt, they dont care anymore...
I decided to take a bus which was supposed to take 6 hours but took 8.5 hoyrs and was the WORST experience of my life....
So I decided to take a flight back to Cairo. I went to the Egyptair office in Sharm to get a one way ticket and was quoted 110 Euros. I had to buy it was I didnt want to take the bus again...
In short....Buy your domestic flights from your own countries and not in Egypt!!!
The fastest and most comfortable way to get to Egypt is by plane. I had no problems when I arrived to Cairo because everything was very well organized but I was very unpleasantly surprised on my way home at the Hurghada airport by the poor organization. I dont know whether this is a characteristic for this particular airport but one must be prepared for slow checking in, baggage carriers who will aggressively try to take you your last euro or two, clerks who dont know to use computers etc.
We took an aeroplane from London to Cairo via Frankfurt. It took around 1.5 hours from London to Frankfurt then 3.5 hours from Frankfurt to Cairo. We flew Lufthansa...of our 11 flights they were probably lower on the scale than the others (although we had what looked like a brand new plane to Cairo).
We flew out of Cairo to Bangkok via Dubai... It took around 3.5 hours to Dubai flying with Singapore Airlines (the best airline in my opinion) and about 6.5 hours to fly Dubai to Bangkok with Thai Airways.
There are direct flights between Cairo and Johannesbur (code-share with SAA).
This was my first time with Egypt Air. Despite hearing negative reports, I do think that this airline was quite satisfactory. (Much better than Olympic, SAA(economy class), & Delta, to name a few).
Egypt Air will soon become a member of Star Alliance.
Leaving from Cairo airport can be confusing. Most international departures go from Terminal 2, except Egypt Air which goes from Terminal 1. While Terminal 1 is reasonably modern its not very well organised and expect it to be a hassle to get through security checks and find your checkin counter. This is definitely an airport to give yourself plenty of time for checkin
Cairo had naturally excellent connections with the rest of Egypt.
There are domestic air flights with destinations that includes Hurghada, Sharm el Sheikh, Luxor, and Aswan
The best way is to take a taxi or a bus.
Get an instant answer from local experts and frequent travelers
Sponsored Links
Sponsored Links


text:
June 19, 2014
First image from 'Fifty Shades of Grey' revealed
Still sees Jamie Dornan's character Christian Grey in his carBuy DVD and Blu-ray
from Amazon UK
The first image from the hugely anticipated Fifty Shades Of Grey movie adaptation has been revealed.
The picture seen above sees Christian Grey (Jamie Dornan) in his car. Dornan replaced Charlie Hunnam in the central role after the Sons Of Anarchy dropped out in October 2013 citing his "immersive TV schedule".
Filming on the Universal Pictures movie was delayed following the sudden exit of Hunnam and last-minute casting of replacement Dornan, recently seen in BAFTA nominated BBC TV series The Fall.
Speaking about how he felt after opting out, Hunnam recently said: "When you put the time into something like that and a character comes alive in your mind, it's heartbreaking not to be able to play him […] It was definitely kind of heartbreaking having to say goodbye to that character and not bring it to life."
The big screen adaptation of EL James's blockbuster erotic novel was originally set to open in cinemas worldwide on August 1, 2014 but will now arrive the following Valentine's Day (February 14, 2015).
Dakota Johnson will co-star as Anastasia Steele, the college graduate who enters into an intense sexual relationship with the older and dominant Grey. Pride And Prejudice actress Jennifer Ehle and True Blood's Luke Grimes will appear in supporting roles.
- Previous: The Penguin and Catwoman revealed in latest 'Gotham' trailer - watch
- Next: Rik Mayall funeral attended by stars of comedy world


text:
It's time for another Durarara!! birthday, and while the site for the upcoming anime still isn't revealing any plans, it is celebrating the June 19th big day for Masaomi Kida with a special digital wallpaper, available through the 25th. Get a look after the jump.
Where do we begin with what those pointy animal ears would do to us, especially when they are on deformed otome game characters? A Japanese otome game developer in Otomate knows all too well and that's exactly what they are offering fans at the Otomate In Nanjatown 2014 event starting from May 10th for about 2 months in Ikebukuro, Japan. See them after the jump!
It's time for some franchises to be extended with new gag manga! Durarara! goes superdeforrmed in Minidura, a Youko Umezu illustrated series joining Dengeki Maoh in the geek media mag's September issue, which went on sale September 27th. Meanwhile, Gundam goes domestic with Gundam Apartments, which recasts Bright Noa and the crew of the original series White Base as apartment tenants. More after the jump.
I was able to have an interview with one of the Guests of Honor, ROOKiEZ is PUNK'D who packed and rocked the San Jose Civic Auditorium on Saturday night during FanimeCon 2013 on Memorial Day weekend in San Jose California. They are a 4 man Alternative rock band who is best known among anime fans for their debut single, "Complication" (Durarara! anime opening theme) and "IN MY WORLD" (Blue Exorcist anime opening theme). Get to know them in part 1 of the interview after the jump!


text:
Computer challenges humans on 'Jeopardy!'
IBM has unveiled an advanced computing system that will compete with humans on a special edition of the television program
Watson, the system is designed to be able to understand complex questions and answer with enough precision and speed to compete on the TV show. Officials from
Jeopardy! said they will produce a human versus machine episode of the program
Produced by Sony Pictures Television and distributed by CBS Television,
Jeopardy! poses a
grand challenge for a computing system due to the variety of subject matter, the speed at which contestants must provide accurate responses and because the clues given to contestants involve analyzing subtle meaning, irony, riddles and other complexities at which humans excel and computers traditionally do not, IBM said.
The scientists said Watson will incorporate massively parallel analytical capabilities and, as human competitors, Watson will not be connected to the Internet or have any other outside assistance.
Watson is a compelling example of how the planet — companies, industries, cities — is becoming smarter, said Samuel Palmisano, IBM chairman, president and chief executive officer.
IBM said the research underlying Watson is expected to elevate computer intelligence and human-to-computer communication to unprecedented levels.